Adjuvant Interferon for Malignant Melanoma

This is a clinical practice guideline for adults with malignant melanoma. The guideline considers whether adjuvant interferon alpha should be offered to patients who have been rendered disease-free following the resection of cutaneous melanomas and who are at high risk for subsequent recurrence. Issues discussed include: steps of treatment, potential side effects, special considerations (such as toxicity, and patient education), and follow-up.